drugset / Trial / NCT00004132
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RandomizedSupportive care
Summary
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of keratinocyte growth factor in preventing oral mucositis in patients who have hematologic cancers and who are undergoing radiation therapy and chemotherapy before autologous peripheral stem cell transplantation.
Timeline
- Start
- 2000-01
- Primary completion
- —
- Completion
- 2004-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palifermin | Protein / enzyme biologic | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Etoposide | Small molecule | — | — |
| Background | Ifosfamide | Small molecule | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Intravenous |